LENZ Therapeutics Q1 2026 Earnings Call Transcript
LENZ Therapeutics, Inc. held its First Quarter 2026 Financial Results Conference Call on May 11, 2026. The call featured key executives including CEO Evert Schimmelpennink, CFO Daniel Chevallard, CCO Shawn Olsson, and CMO Dr. Marc Odrich. They addressed analysts from major financial institutions such as TD Cowen, Citigroup, Piper Sandler, Leerink Partners, William Blair, and H.C. Wainwright. The session began with prepared remarks from management, followed by a question-and-answer segment. CFO Daniel Chevallard opened the discussion by highlighting that the call contained forward-looking statements regarding the company's future expectations, corporate strategy, regulatory plans, and cash runway projections. He cautioned listeners that actual results might differ materially from these projections due to various risks detailed in SEC filings. This transcript provides insights into the company's financial health and strategic direction for the quarter, offering stakeholders a direct look at management's responses to analyst inquiries regarding commercial and medical developments.
Wire timeline
LENZ Therapeutics Q1 2026 Earnings Call Transcript
LENZ Therapeutics, Inc. held its First Quarter 2026 Financial Results Conference Call on May 11, 2026. The call featured key executives including CEO Evert Schimmelpennink, CFO Daniel Chevallard, CCO Shawn Olsson, and CMO Dr. Marc Odrich. They addressed analysts from major financial institutions such as TD Cowen, Citigroup, Piper Sandler, Leerink Partners, William Blair, and H.C. Wainwright. The session began with prepared remarks from management, followed by a question-and-answer segment. CFO Daniel Chevallard opened the discussion by highlighting that the call contained forward-looking statements regarding the company's future expectations, corporate strategy, regulatory plans, and cash runway projections. He cautioned listeners that actual results might differ materially from these projections due to various risks detailed in SEC filings. This transcript provides insights into the company's financial health and strategic direction for the quarter, offering stakeholders a direct look at management's responses to analyst inquiries regarding commercial and medical developments.
All Articles on Seeking Alpha